TKPYY - Takeda Pharmaceutical Company Limited

Other OTC - Other OTC Delayed Price. Currency in USD
20.795
+0.095 (+0.46%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close20.700
Open20.785
Bid0.000 x 0
Ask0.000 x 0
Day's Range20.752 - 20.890
52 Week Range18.930 - 31.290
Volume172,541
Avg. Volume542,996
Market Cap32.723B
Beta0.86
PE Ratio (TTM)29.94
EPS (TTM)0.695
Earnings DateN/A
Forward Dividend & Yield0.81 (3.93%)
Ex-Dividend Date2018-03-28
1y Target EstN/A
Trade prices are not sourced from all markets
  • The Wall Street Journal13 days ago

    [$$] Third Rock, Takeda Launch Regenerative Medicine Startup for Liver Diseases

    Co. are launching Ambys Medicines with $140 million to develop regenerative medicines for liver diseases. Some 3.9 million U.S. adults have been diagnosed with liver disease, according to the Centers for Disease Control and Prevention. Ambys, formed by Third Rock and Takeda this year, is capitalizing on improved understanding of liver biology and advances in cell and gene therapy to treat liver conditions.

  • ACCESSWIRE21 days ago

    Takeda Pharmaceutical Co. Ltd. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / July 31, 2018 / Takeda Pharmaceutical Co. Ltd. (OTC PINK: TKPYY ) will be discussing their earnings results in their Q1 Earnings Call to be held on July 31, 2018 at 5:00 PM ...

  • Shire profit edges higher ahead of Takeda sale
    Reuters21 days ago

    Shire profit edges higher ahead of Takeda sale

    Shire (SHP.L), the London-listed pharmaceutical group being bought by Japan's Takeda , reported a 4 percent rise in second-quarter earnings as revenue rose 5 percent to $3.92 billion, just ahead of market expectations. Earlier on Tuesday, Takeda said its first-quarter operating profit had halved from a year ago, when it had booked gains from asset sales. It is buying Shire to broaden its drugs portfolio and plug a gap in its late-stage pipeline.

  • Takeda operating profit halves, looks to asset sales to shore up finances
    Reuters21 days ago

    Takeda operating profit halves, looks to asset sales to shore up finances

    Japan's Takeda Pharmaceutical Co Ltd on Tuesday reported that its operating profit halved from the year-ago quarter, when the drugmaker had booked gains from asset sales. Takeda has sold off assets it sees as non-core or underperforming, with Chief Executive Christophe Weber saying on Tuesday he was open to further disposals as the drugmaker looks to shore up its stretched finances. Many of Takeda's top-performing drugs posted stronger sales in the first quarter, but the company is facing a weak late-stage pipeline.

  • The Wall Street Journal28 days ago

    [$$] Takeda Pharma Says It Plans No U.S. Drug Price Increases in 2018

    Co. (4502.TO) told Dow Jones Newswires on Tuesday it has no plans to increase prices in the U.S. in 2018, the latest major drugmaker to take such a step. Last week, Novartis AG (NOVN.EB) and Merck & Co. (MRK) made similar pledges. Novartis said it wouldn’t raise U.S. drug prices, and Merck said it would lower them for certain drugs.

  • Takeda Bets on China for Global Growth 
    Bloomberglast month

    Takeda Bets on China for Global Growth 

    Takeda Pharmaceutical Co. sees China becoming a “core country” for its global growth strategy and is optimistic its $62 billion acquisition of Shire Plc will win approval by the country’s regulators. Takeda is preparing to begin selling seven new drugs in China in the next five years, more than in any other region, while working to secure reimbursement for them under the country’s medical insurance program, Chief Executive Officer Christophe Weber said in an interview in Beijing. “There’s no reason in the long term China shouldn’t be our second-biggest business in the world,” Weber said.

  • TheStreet.comlast month

    PepsiCo, Brett Kavanaugh, Fox and IHOP (or IHOb?) - 5 Things You Must Know

    U.S. stock futures rose modestly on Tuesday, July 10, and global stocks traded mostly higher following one of the strongest sessions on Wall Street in over a month, as investors slowly switched their focus to the upcoming corporate earnings season.

  • Japan's Takeda gains U.S. approval for $62 billion Shire buy
    Reuterslast month

    Japan's Takeda gains U.S. approval for $62 billion Shire buy

    Takeda Pharmaceutical Co Ltd on Tuesday said it has received U.S. approval for its $62 billion (46.9 billion pounds) acquisition of London-listed Shire Plc (SHP.L), taking the Japanese firm one step closer to its goal of becoming a global top 10 drugmaker. Takeda in a press release said it received unconditional clearance from the United States Federal Trade Commission. The Tokyo-listed firm is still awaiting approval from regulators in China, the European Union and elsewhere, as well from shareholders of both parties.

  • Japan's Takeda gains U.S. approval for $62 billion Shire buy
    Reuterslast month

    Japan's Takeda gains U.S. approval for $62 billion Shire buy

    Takeda Pharmaceutical Co Ltd on Tuesday said it has received U.S. approval for its $62 billion acquisition of London-listed Shire Plc, taking the Japanese firm one step closer to its goal of becoming a global top 10 drugmaker. Takeda in a press release said it received unconditional clearance from the United States Federal Trade Commission. The Tokyo-listed firm is still awaiting approval from regulators in China, the European Union and elsewhere, as well from shareholders of both parties.

  • New Takeda HQ Flaunts Global Ambition Alongside Japan Roots
    Bloomberg2 months ago

    New Takeda HQ Flaunts Global Ambition Alongside Japan Roots

    Embedded in the sleek metallic and cypress interior of Takeda Pharmaceutical Co.’s new global headquarters in Tokyo are stylized Japanese characters for words like life, water and light. Melding futuristic design with traditional Japanese elements highlights the balancing act facing Chief Executive Officer Christophe Weber: showing he can honor the 237-year-old drugmaker’s Japanese heritage as he tries to complete the biggest deal in Takeda’s history -- the $62 billion takeover of Shire Plc. “He’s very quick to say they’re still a Japanese company, but at the same time making a point to say they’re not Japanese because they have a very international, global executive team,” said John W. Carlson, chair of the health-care committee at the American Chamber of Commerce in Japan.

  • Takeda shareholders bin proposal from anti-Shire group; only 10 percent in favour
    Reuters2 months ago

    Takeda shareholders bin proposal from anti-Shire group; only 10 percent in favour

    A group of Takeda Pharmaceutical Co Ltd shareholders, who are trying to build support to block the $62 billion (47.36 billion pounds) acquisition of London-listed Shire Plc (SHP.L), failed to get a proposal passed at the drugmaker's annual general meeting (AGM) on Thursday. The proposal - to require advance shareholder approval for large acquisitions - received about 10 percent of votes in favour, the company confirmed to Reuters, casting doubt on the group's ability to gather enough support to scupper the Shire deal. The Shire deal would turn Takeda into one of the world's largest drugmakers but the group says it would require taking on too much financial risk.

  • Takeda shareholders bin proposal from anti-Shire group; only 10 percent in favor
    Reuters2 months ago

    Takeda shareholders bin proposal from anti-Shire group; only 10 percent in favor

    A group of Takeda Pharmaceutical Co Ltd shareholders, who are trying to build support to block the $62 billion acquisition of London-listed Shire Plc (SHP.L), failed to get a proposal passed at the drugmaker's annual general meeting (AGM) on Thursday. The proposal - to require advance shareholder approval for large acquisitions - received about 10 percent of votes in favor, the company confirmed to Reuters, casting doubt on the group's ability to gather enough support to scupper the Shire deal. The Shire deal would turn Takeda into one of the world's largest drugmakers but the group says it would require taking on too much financial risk.

  • Takeda’s CEO on China, Cancer Drugs and Alzheimer’s Disease
    Bloomberg2 months ago

    Takeda’s CEO on China, Cancer Drugs and Alzheimer’s Disease

    Christophe Weber, the first foreign-born chief executive officer of Japan’s Takeda Pharmaceutical Co., last month inked a $62 billion takeover of rare-disease drugmaker Shire Plc. The deal will reshape the 237-old, Osaka-based company into a global powerhouse. In a recent interview in Manhattan, the French-born CEO talked about exciting areas of research and the potential of China. It used to take years to get the Essential Drug List [a list of medicines covered by the national medical insurance] updated in China.

  • How Takeda CEO Sells Japan's Biggest Deal to Doubters
    Bloomberg2 months ago

    How Takeda CEO Sells Japan's Biggest Deal to Doubters

    Christophe Weber says growth and innovation are the metrics to success in Takeda Pharmaceutical Co.’s $62 billion purchase of Shire Plc. The first order of business is bringing global shareholders around to Japan’s biggest-ever outbound takeover. The Takeda chief executive officer is facing a 21 percent drop in the stock price since the company disclosed its interest in March, while Shire is trading 9 pounds ($12) below the offer price of roughly 49 pounds a share. In an interview at Takeda’s new Tokyo headquarters, the French-born CEO discusses his push to sell the deal overseas -- and in Japan -- and plans to integrate the 237-year-old drugmaker with a London-listed company with mostly U.S.-based operations.

  • Reuters2 months ago

    Takeda shareholder group aims to block $62 billion Shire deal

    A group of Takeda Pharmaceutical Co Ltd shareholders is trying to build support to block the $62 billion (46.4 billion pounds) acquisition of London-listed Shire Plc (SHP.L) at an extraordinary general meeting, a leading member of the group told Reuters on Monday. Takeda will hold the shareholder meeting later this year or early next year to approve an issue of new stock to help fund the Shire deal, making it a de facto vote on the deal itself. The 130 member group formed by ex-Takeda employees holds one percent of the drugmaker's shares, and needs to secure a third of shareholder votes.